Zacks Research Issues Negative Forecast for Masimo Earnings

Masimo Co. (NASDAQ:MASI - Free Report) - Analysts at Zacks Research cut their Q2 2025 EPS estimates for Masimo in a note issued to investors on Tuesday, May 27th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical equipment provider will earn $1.22 per share for the quarter, down from their prior estimate of $1.28. The consensus estimate for Masimo's current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo's Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.23 EPS, FY2025 earnings at $4.95 EPS, Q1 2026 earnings at $1.28 EPS, Q2 2026 earnings at $1.34 EPS, Q3 2026 earnings at $1.27 EPS, Q4 2026 earnings at $1.44 EPS, FY2026 earnings at $5.34 EPS and FY2027 earnings at $5.95 EPS.

Several other equities research analysts also recently weighed in on MASI. Wells Fargo & Company reduced their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. BTIG Research set a $193.00 target price on shares of Masimo and gave the stock a "buy" rating in a report on Wednesday, May 7th. Wall Street Zen cut shares of Masimo from a "buy" rating to a "hold" rating in a report on Friday. Piper Sandler restated an "overweight" rating and issued a $200.00 target price (down previously from $215.00) on shares of Masimo in a report on Wednesday, May 7th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $191.60.

Masimo Stock Up 2.8%

Shares of NASDAQ MASI traded up $4.39 on Friday, reaching $161.36. 1,085,666 shares of the company's stock traded hands, compared to its average volume of 649,664. Masimo has a 12 month low of $101.61 and a 12 month high of $194.88. The business's 50 day simple moving average is $157.13 and its two-hundred day simple moving average is $167.19. The company has a market cap of $8.75 billion, a price-to-earnings ratio of 111.28 and a beta of 1.23. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $372.00 million during the quarter, compared to the consensus estimate of $367.79 million. During the same quarter in the prior year, the company earned $0.77 earnings per share. The firm's revenue for the quarter was down 24.5% on a year-over-year basis.

Hedge Funds Weigh In On Masimo

Several hedge funds have recently added to or reduced their stakes in MASI. Jones Financial Companies Lllp bought a new position in Masimo during the 4th quarter valued at about $27,000. Twin Tree Management LP bought a new position in Masimo during the 1st quarter valued at about $29,000. Blue Trust Inc. grew its holdings in Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Masimo by 128.9% during the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 116 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 64 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Insider Transactions at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the transaction, the chief operating officer now owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,053 shares of company stock worth $6,998,565 in the last 90 days. 9.70% of the stock is currently owned by insiders.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.